RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the pricing of its offering of $55 million aggregate principal amount of 5.5% convertible senior notes due 2028 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Salix has also granted an option to the initial purchasers of the notes to purchase up to an additional $5.0 million aggregate principal amount of notes to cover over-allotments.
